Research programme: autoimmune disease therapeutics - National Institutes of Health/Wellstat ImmunoTherapeutics
Latest Information Update: 18 Jul 2016
At a glance
- Originator National Institutes of Health (USA); Wellstat ImmunoTherapeutics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 18 Jul 2016 Early research in Autoimmune disorders in USA (unspecified route)